Should I buy or sell Anixa Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIX shares. View ANIX analyst ratings or view top-rated stocks .

What is Anixa Biosciences' stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Anixa Biosciences' stock. Their ANIX share price targets range from $12.00 to $12.00. On average, they predict the company's share price to reach $12.00 in the next year. This suggests a possible upside of 277.4% from the stock's current price. View analysts price targets for ANIX or view top-rated stocks among Wall Street analysts .

How have ANIX shares performed in 2024?

Anixa Biosciences' stock was trading at $3.88 at the beginning of 2024. Since then, ANIX shares have decreased by 18.0% and is now trading at $3.18. View the best growth stocks for 2024 here .

When is Anixa Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our ANIX earnings forecast .

How were Anixa Biosciences' earnings last quarter?

Anixa Biosciences, Inc. (NASDAQ:ANIX) posted its earnings results on Tuesday, March, 12th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01.

What other stocks do shareholders of Anixa Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anixa Biosciences investors own include Cronos Group (CRON) , Innovative Industrial Properties (IIPR) , Roku (ROKU) , Ally Financial (ALLY) , Albireo Pharma (ALBO) , Air Lease (AL) , Akoustis Technologies (AKTS) , Akero Therapeutics (AKRO) , Aimmune Therapeutics (AIMT) and Advanced Emissions Solutions (ADES) .

How do I buy shares of Anixa Biosciences?

Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ANIX

Anixa Biosciences (ANIX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ANIX Stock Alerts

$3.12

+0.02 (+0.65%)

(As of 05:21 PM ET)

Compare

Today's Range: $3.05
▼
$3.20
50-Day Range: $3.05
▼
$4.51
52-Week Range: $2.75
▼
$5.13

Volume: 32,692 shs
Average Volume: 139,408 shs
Market Capitalization: $99.53 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Get Anixa Biosciences alerts:

Anixa Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 277.4% Upside
$12.00 Price Target
Short Interest: Healthy
1.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.58
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$182,130 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.44) to ($0.45) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

Medical Sector

429th out of 918 stocks

Pharmaceutical Preparations Industry

193rd out of 418 stocks

3.5

Analyst's Opinion

Consensus Rating
Anixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Anixa Biosciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.90% of the float of Anixa Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Anixa Biosciences has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Anixa Biosciences has recently decreased by 3.57%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Anixa Biosciences does not currently pay a dividend.
Dividend Growth
Anixa Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANIX.

1.3

News and Social Media Coverage

News Sentiment
Anixa Biosciences has a news sentiment score of -0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Anixa Biosciences this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
7 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $182,130.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
22.60% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 29.13% of the stock of Anixa Biosciences is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.44) to ($0.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anixa Biosciences is -9.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anixa Biosciences is -9.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anixa Biosciences has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Anixa Biosciences Stock (NASDAQ:ANIX)

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

ANIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANIX Stock News Headlines

April 11, 2024 | insidertrades.com

Lewis H. Titterton, Jr. Acquires 15,009 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) Stock

April 18, 2024 | finance.yahoo.com

Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 14, 2024 | americanbankingnews.com

Head-To-Head Survey: PainReform (NASDAQ:PRFX) & Anixa Biosciences (NASDAQ:ANIX)

April 12, 2024 | americanbankingnews.com

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Acquires $49,229.52 in Stock

March 16, 2024 | finance.yahoo.com

ANIX Apr 2024 2.500 put

March 16, 2024 | finance.yahoo.com

ANIX Apr 2024 7.500 call

March 14, 2024 | prnewswire.com

Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 12, 2024 | benzinga.com

Recap: Anixa Biosciences Q1 Earnings

March 11, 2024 | prnewswire.com

Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress

February 22, 2024 | benzinga.com

Anixa Biosciences Stock (NASDAQ:ANIX) Insider Trades

February 21, 2024 | investing.com

Anixa Biosciences Inc (ANIX)

February 17, 2024 | finance.yahoo.com

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

February 17, 2024 | finance.yahoo.com

ANIX Feb 2024 5.000 call

February 13, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Anixa Biosciences (ANIX) and InMode (INMD)

February 12, 2024 | finanznachrichten.de

Anixa Biosciences, Inc.: Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial

February 12, 2024 | finance.yahoo.com

Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial

February 6, 2024 | finance.yahoo.com

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023

January 30, 2024 | ca.finance.yahoo.com

Dogs Can Suffer from Depression — Here Are Signs to Look Out for and How to Diagnosis Them

January 30, 2024 | msn.com

Here’s Why You Get a Runny Nose When You’re Eating

January 30, 2024 | ca.news.yahoo.com

Visible wants to track your illness, more than your fitness

January 30, 2024 | ca.finance.yahoo.com

Recalled cinnamon applesauce pouches were never tested for lead, FDA reports

January 30, 2024 | ca.style.yahoo.com

If You Suffer From Intense PMS, This Condition Could Be The Cause

January 30, 2024 | ca.style.yahoo.com

King Charles smiles as he leaves hospital following prostate procedure

January 30, 2024 | msn.com

Kristen Dahlgren: Why I’m leaving NBC to launch a nonprofit to make breast cancer vaccines a reality

January 29, 2024 | finance.yahoo.com

Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference

See More Headlines

Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/19/2024
Next Earnings (Estimated): 6/12/2024
Fiscal Year End: 10/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ANIX
CUSIP: N/A
CIK: 715446
Web: www.anixa.com
Phone: (408) 708-9808
Fax: 631-549-5974
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.00
High Stock Price Target: $12.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +284.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,810,000.00
Net Margins: N/A
Pretax Margin: -5,174.29%
Return on Equity: -44.09%
Return on Assets: -40.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.19
Quick Ratio: 15.19

Sales & Book Value

Annual Sales: $210,000.00
Price / Sales: 473.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.75 per share
Price / Book: 4.16

Miscellaneous

Outstanding Shares: 31,900,000
Free Float: 24,691,000
Market Cap: $99.53 million
Optionable: Optionable
Beta: 0.84

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Amit Kumar Ph.D. (Age 60)
CEO, Chairman & Co-Chair of CBAB
Comp: $1.29M
Mr. Michael J. Catelani CPA (Age 57)
MBA, President, COO, CFO & Corporate Secretary
Comp: $788.83k
Mr. John Roop (Age 74)
Senior Vice President of Engineering
Comp: $275k
Dr. Pamela D. Garzone Ph.D. (Age 69)
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ANIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Anixa Biosciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIX shares.
View ANIX analyst ratings or view top-rated stocks.
What is Anixa Biosciences' stock price target for 2024?: 1 equities research analysts have issued twelve-month target prices for Anixa Biosciences' stock. Their ANIX share price targets range from $12.00 to $12.00. On average, they predict the company's share price to reach $12.00 in the next year. This suggests a possible upside of 277.4% from the stock's current price.
View analysts price targets for ANIX or view top-rated stocks among Wall Street analysts.
How have ANIX shares performed in 2024?: Anixa Biosciences' stock was trading at $3.88 at the beginning of 2024. Since then, ANIX shares have decreased by 18.0% and is now trading at $3.18.
View the best growth stocks for 2024 here.
When is Anixa Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our ANIX earnings forecast.

How were Anixa Biosciences' earnings last quarter?: Anixa Biosciences, Inc. (NASDAQ:ANIX) posted its earnings results on Tuesday, March, 12th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01.
What other stocks do shareholders of Anixa Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL), Akoustis Technologies (AKTS), Akero Therapeutics (AKRO), Aimmune Therapeutics (AIMT) and Advanced Emissions Solutions (ADES).
How do I buy shares of Anixa Biosciences?: Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial